Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Haemonetics (HAE) EPS (Weighted Average and Diluted) (2016 - 2025)

Haemonetics has reported EPS (Weighted Average and Diluted) over the past 17 years, most recently at $0.95 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 28.38% year-over-year to $0.95; the TTM value through Dec 2025 reached $3.63, up 42.91%, while the annual FY2025 figure was $3.31, 44.54% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $0.95 at Haemonetics, up from $0.81 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at $1.17 in Q1 2025 and troughed at -$0.22 in Q2 2021.
  • A 5-year average of $0.55 and a median of $0.62 in 2022 define the central range for EPS (Weighted Average and Diluted).
  • Biggest five-year swings in EPS (Weighted Average and Diluted): plummeted 164.71% in 2021 and later surged 522.22% in 2022.
  • Year by year, EPS (Weighted Average and Diluted) stood at $0.29 in 2021, then soared by 120.69% to $0.64 in 2022, then fell by 4.69% to $0.61 in 2023, then grew by 21.31% to $0.74 in 2024, then rose by 28.38% to $0.95 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for HAE at $0.95 in Q4 2025, $0.81 in Q3 2025, and $0.7 in Q2 2025.